What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single unit does powder of active substance (CM-AT) administered 3 times per day”In the company’s words, NCT02649959 on ClinicalTrials.gov
- Tested for
- Autism
- Main trialPhase 3
- “This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.”In the company’s words, NCT02649959 on ClinicalTrials.gov
Coming up1
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jan 2028 | An Open Label Study of CM-AT for the Treatment of Children With Autism | |
| Phase 3Completed | 22 Dec 2017 | A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026